摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl-methyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbodithioic acid 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl ester | 1414847-39-4

中文名称
——
中文别名
——
英文名称
1-(3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl-methyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbodithioic acid 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl ester
英文别名
2-(1,3-dioxoisoindol-2-yl)ethyl (1R)-1-[[(2R,3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbodithioate
1-(3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl-methyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbodithioic acid 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl ester化学式
CAS
1414847-39-4
化学式
C40H47N3O6S2
mdl
——
分子量
729.962
InChiKey
WXRAWLZOXISXII-ZNYQLVTFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.9
  • 重原子数:
    51
  • 可旋转键数:
    11
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    138
  • 氢给体数:
    0
  • 氢受体数:
    9

反应信息

  • 作为产物:
    描述:
    N-(2-溴乙基)邻苯二甲酰亚胺sodium 1-(3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylmethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbodithioate乙腈 为溶剂, 反应 24.0h, 以27.4%的产率得到1-(3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl-methyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbodithioic acid 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl ester
    参考文献:
    名称:
    盐酸艾美汀的二硫代氨基甲酸酯衍生物在前列腺癌细胞系中的设计,合成及细胞毒性研究
    摘要:
    通过使依替丁的N2'-位衍生化,合成了一个少量的依替丁二硫代氨基甲酸酯衍生物库,产率为25-86%。这些化合物在雄激素受体阳性LNCaP和雄激素受体阴性PC3和DU145前列腺癌细胞系中的抗癌评估显示出时间依赖性和剂量依赖性细胞毒性。除化合物4c外,本研究中的所有二硫代氨基甲酸酯类似物在所有前列腺癌细胞系中均显示出显着的效力(无论是雄激素受体阳性还是阴性),其细胞毒性IC 50值范围为1.312±0.032μM。治疗第7天时为5.201±0.125μM。与二硫代氨基甲酸钠盐1相比,所有二硫代氨基甲酸酯类似物(2和4a – 4g  )在治疗的第7天显示出比化合物1(PC3,IC 50  = 0.087±0.005μM; DU145,IC 50  = 0.079±0.003μM和LNCaP,IC 50 = 0.079± 0.003μM)低的细胞毒性。因此,似乎化合物1的S-烷基化导致更稳定的二
    DOI:
    10.1016/j.bmc.2015.06.072
点击查看最新优质反应信息

文献信息

  • Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines
    作者:Emmanuel S. Akinboye、Zebalda D. Bamji、Bernard Kwabi-Addo、David Ejeh、Robert L. Copeland、Samuel R. Denmeade、Oladapo Bakare
    DOI:10.1016/j.bmc.2015.06.072
    日期:2015.9
    salt 1, all the dithiocarbamate ester analogs (2 and 4a–4g) displayed lower cytotoxicity than compound 1 (PC3, IC50 = 0.087 ± 0.005 μM; DU145, IC50 = 0.079 ± 0.003 μM and LNCaP, IC50 = 0.079 ± 0.003 μM) on day 7 of treatment. Consequently, it appears that S-alkylation of compound 1 leads to a more stable dithiocarbamate ester derivative that resulted in lower anticancer activity in the prostate cancer
    通过使依替丁的N2'-位衍生化,合成了一个少量的依替丁二硫代氨基甲酸酯衍生物库,产率为25-86%。这些化合物在雄激素受体阳性LNCaP和雄激素受体阴性PC3和DU145前列腺癌细胞系中的抗癌评估显示出时间依赖性和剂量依赖性细胞毒性。除化合物4c外,本研究中的所有二硫代氨基甲酸酯类似物在所有前列腺癌细胞系中均显示出显着的效力(无论是雄激素受体阳性还是阴性),其细胞毒性IC 50值范围为1.312±0.032μM。治疗第7天时为5.201±0.125μM。与二硫代氨基甲酸钠盐1相比,所有二硫代氨基甲酸酯类似物(2和4a – 4g  )在治疗的第7天显示出比化合物1(PC3,IC 50  = 0.087±0.005μM; DU145,IC 50  = 0.079±0.003μM和LNCaP,IC 50 = 0.079± 0.003μM)低的细胞毒性。因此,似乎化合物1的S-烷基化导致更稳定的二
查看更多

同类化合物

盐酸吐根酚碱 盐酸吐根碱 吐根碱氢溴酸盐 吐根碱氢溴酸盐 吐根碱 依米丁二盐酸盐水合物 依米丁 二盐酸吐根碱 九节碱 7',10,11-三甲氧基-1',2'-二去氢依米丁-6'-醇草酸盐(1:1) 2-[(6,7-二甲氧基-1,2,3,4-四氢异喹啉-1-基)甲基]-3-乙基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉四水合物二盐酸盐 1',2'-二去氢-7',10,11-三甲氧基依米丁-6',9-二醇 (+)-吐根素二盐酸盐水合物 (1RS,2S,3R,11bR)-2-benzoyl-1-(3-ethyl-9,10-dimethoxy-4-oxo-1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizin-2-ylmethyl)-6-7-dimethoxy-1,2-dihydroisoquinoline-1-carbonitrile (2SR,3RS,11bSR)-2-benzoyl-1-(3-ethyl-9,10-dimethoxy-4-oxo-1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizin-2-ylmethyl)-6,7-dimethoxy-1,2-dihydroisoquinoline-1-carbonitrile 2'-N-(1''-deoxy-1''-β-D-fructopyranosyl)cephaeline 7'-O-demethylcephaeline 7′,10-dide-O-methylcephaeline 2′-(N-carboxy-β-alanyl)-tert-butyl emetine ester 7'-O-demethylisocephaeline N-Methyl-emetin Emetine (or isoemetine), dihydrochloride Emetine hydrobromide 2H-Benzo(a)quinolizine, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-(3-(o-anisyloxy)-2-hydroxypropyl)-1-isoquinolyl)methyl)-, dihydrochloride 2H-Benzo(a)quinolizine, 3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-((1,2,3,4-tetrahydro-6-isopentoxy-7-methoxy-1-isoquinolyl)methyl)-, phosphate (2S,3R,11bS)-2-[[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine;triiodobismuthane 2-[(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine;hydron;dichloride 11b-epi-emetine 11b-epi-isoemetine (2S,3R,11bS)-2-[(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine;hydron;dibromide 1-[(1R)-1-[[(2R,3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-3-tert-butylsulfanylpropan-2-ol;hydron;dichloride Emetine, 2'-(3-(6-chloro-o-toluidino)-2-hydroxypropyl)-, trihydrochloride Emetine, 2'-(2-hydroxy-3-(4-methyl-1-piperazinyl)propyl)-, tetrahydrochloride 1-[(1R)-1-[[(2R,3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-3-(furan-2-ylmethylsulfanyl)propan-2-ol;hydron;dichloride 2H-Benzo(a)quinolizine, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-(3-(2-ethylhexyloxy)-2-hydroxypropyl)-1-isoquinolyl)methyl)-, dihydrochloride 2H-Benzo(a)quinolizine, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-(2-hydroxy-3-(1-methylpropylthio)propyl)-1-isoquinolyl)methyl)-, dihydrochloride, trihydrate 2H-Benzo(a)quinolizine, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-(3-(3,4-dimethoxycarbaniloylmethylthio)-2-hydroxypropyl)-1-isoquinolyl)methyl)-, dihydrochloride <2S-<2α(S*),3β,11β>>-9-benzyloxy-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydro-1-isoquinolyl)methyl-3-ethyl-1,3,4,6,7,11b-hexahydro-10-methoxy-2H-benzoquinolizine <2S-<2α(S*),3β,11β>>-3-ethyl-1,3,4,6,7,11b-hexahydro-9-hydroxy-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydro-1-isoquinolyl)methyl-10-methoxy-2H-benzoquinolizine <2S-<2α(R*),3β,11β>>-9-benzyloxy-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydro-1-isoquinolyl)methyl-3-ethyl-1,3,4,6,7,11b-hexahydro-10-methoxy-2H-benzoquinolizine Emetine, N-(1-carboxyprolyl)-, benzyl ester Emetine, 2'-(N-carboxyglycyl)-, tert-butyl ester Emetine dihydrobromide tetrahydrate 16,17-Dinoremetan, 1-ethyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-beta)-(+-)- 16,17-Dinoremetan, 1-methyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-alpha,2-alpha)-(+-)- 16,17-Dinoremetan, 1-methyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-beta)-(+-)- 16,17-Dinoremetan, 1',2'-didehydro-1-methyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-alpha)-(+-)- 16,17-Dinoremetan, 1',2'-didehydro-1-methyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-beta)-(+-)- 16,17-Dinoremetan, 1-methyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-alpha)-(+-)- 16,17-Dinoremetan, 1',2'-didehydro-1-methyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-alpha,2-alpha)-(+-)-